about
Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationChildhood immune thrombocytopenia: Clinical presentation and managementAlternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Are there more tricks in the bag for treating thrombocytopenia?Current treatment options for primary immune thrombocytopenia.Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia.Romiplostim for the treatment of primary immune thrombocytopenia.A megakaryocyte with no platelets: anti-platelet antibodies, apoptosis, and platelet production.New insights into thrombopoiesis in neonatal sepsis.High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes.Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.Preliminary nonclinical toxicity, pharmacokinetics, and pharmacodynamics of ALXN4100TPO, a thrombopoietin receptor agonist, in CD2F1 mice.Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.The biology of thrombopoietin and thrombopoietin receptor agonists.Romiplostim for management of chemotherapy-induced thrombocytopenia.Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitroEltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.The incredible journey: From megakaryocyte development to platelet formation.Infusion of Trx-1-overexpressing hucMSC prolongs the survival of acutely irradiated NOD/SCID mice by decreasing excessive inflammatory injuryHistorical perspective and future directions in platelet research.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.The current status of thrombopoietins in the management of liver disease.The last intron of the human thrombopoietin gene enhances expression in milk of transgenic mice.Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura.Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.
P2860
Q24198795-2F754B45-B2AA-4548-86C0-694F1809F233Q27023294-F9EBB00B-C169-4C19-9A08-63A2BD69E002Q30248355-DA970B18-1836-4639-A8CB-9B701B1DD307Q30399669-D8608622-724C-4D11-8150-7EF70F202088Q33392442-72A42CEF-41D0-4964-93E8-767BCE282E3EQ33394149-D1C8CA3B-C748-43E1-AA20-39570066374BQ33397092-C835734C-F967-43D5-BDEB-06124531789DQ33398217-F7F4B976-DAE2-4696-A92D-85BF94DF88E8Q33400560-197780CA-A5FD-48D2-9903-2D4E9CABFFB6Q33402025-434642A6-0002-4E84-A2AC-BD9F30A67D8DQ33402060-30A1EE73-AC95-439E-A128-AD5A0EFDEEAAQ33405562-68C19C11-57B8-4D02-90E5-AD6F8633AB1DQ33406166-57505488-4806-4D48-82B2-077756317B85Q33406871-752B6A69-8BB5-4725-9DB1-0E0A8C0CD53EQ33407110-3CAC3D1E-CAC6-4B17-89F7-FA693B700DD7Q33408850-75B4E78C-A5C9-4EEB-B110-32565906755FQ33412605-FE6F9D87-E92D-491B-916E-71862F2FD4B1Q33412896-E9B7C140-254B-4605-9495-DD12A4CCDC96Q33414573-D2881632-F251-4DB3-80A9-4FE1F0720B6FQ33418722-027F92E3-117A-4AE1-A740-C17C8AC3334DQ33420441-CA15C5F9-A2CE-4BB9-9FB3-68501AFB24EAQ33428724-0B32EE75-FA18-43D0-AA51-189FF9D29CACQ33431320-1348E3BE-508D-43C9-B8FC-E840F3F2F82AQ34037117-6B80905C-D52D-4C3A-97EC-05FBDFB773F7Q35040845-407811AE-0F3E-4776-8384-63793CB79964Q35185593-16CD5F98-D6B0-4F80-8E4E-F3041B9EB686Q38100790-6F9169BA-BE6C-4C04-A2D7-45B7BA98D26DQ42589644-742D339A-0717-43B9-838E-862FED331201Q46784360-AC88F980-993E-4AB2-92DF-2F511CD48F16Q47720114-542C4E34-C5C2-4B3D-A22B-50A2ACCB2AA4Q52732629-AA99C020-A3A0-4D5D-99B3-8037EB815D81
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Biology and chemistry of thrombopoietic agents
@ast
Biology and chemistry of thrombopoietic agents
@en
type
label
Biology and chemistry of thrombopoietic agents
@ast
Biology and chemistry of thrombopoietic agents
@en
prefLabel
Biology and chemistry of thrombopoietic agents
@ast
Biology and chemistry of thrombopoietic agents
@en
P2860
P1476
Biology and chemistry of thrombopoietic agents
@en
P2093
David J Kuter
P2860
P304
P356
10.1053/J.SEMINHEMATOL.2010.02.005
P577
2010-07-01T00:00:00Z